![Stocks To Watch Today (23 Apr 2024): Gallantt Metal Hits New All-Time High, TECHNOE Brews 52-Week High & More](https://stockpricearchive.com/wp-content/uploads/2024/04/tue-23-apr-2024-stocks-to-watch-150x150.webp)
Home / Share Price Target / Jenburph
Jenburkt Pharmaceuticals Share Price Target 2024, 2025, 2026 to 2039 With Charts
Jenburkt Pharmaceuticals Limited | |||
![]() | Symbol: JENBURPH | ||
Price: ₹1,137 | |||
Exchange: BSE | |||
-> |
Show Table of Contents
Table of Contents
- 0.1: Jenburkt Pharmaceuticals Financial Performance
- 0.1.1: Is Jenburkt Pharmaceuticals A Good Buy For Long Term?
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Jenburkt Pharmaceuticals Share Price Target For 2024
- 1.1.1: Jenburkt Pharmaceuticals Share Price Target Table For 2024
- 1.1.2: Summary: Jenburkt Pharmaceuticals Share Price Prediction For 2024
- 1.2: Jenburkt Pharmaceuticals Share Price Target For 2025
- 1.2.1: Jenburkt Pharmaceuticals Share Price Target Table For 2025
- 1.2.2: Summary: Jenburkt Pharmaceuticals Share Price Prediction For 2025
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Jenburkt Pharmaceuticals Long Term Share Price Prediction Chart From 2024, 2025, 2026 to 2039
- 2.2: Jenburkt Pharmaceuticals Share Price Target Table From 2024, 2025, 2026 to 2039
- 3: Jenburkt Pharmaceuticals Past Performance
Advertisement
Jenburkt Pharmaceuticals Financial Performance
Metric | Value | Description |
---|---|---|
Market Capital | 542.78 Crore | Market valuation of Jenburkt Pharmaceuticals's shares. |
Revenue (TTM) | 141.63 Crore | Total revenue generated by Jenburkt Pharmaceuticals over the past twelve months. |
Net Income (TTM) | +25.97 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
Operating Margin | 24.99% | Income from operations as a percentage of revenue, before taxes and interest. |
Profit Margin | 78.01% | Net income as a percentage of revenue, after all expenses. |
Revenue Growth (Quarterly) | -15.52% | Change in revenue compared to the previous quarter. |
Earnings Growth (YOY Quarterly) | +11.51% | Change in earnings compared to the same quarter last year. |
Total Cash | 4.08 Crore | Total amount of liquid funds available to Jenburkt Pharmaceuticals. |
Is Jenburkt Pharmaceuticals A Good Buy For Long Term?
Jenburkt Pharmaceuticals shows strong recent performance with impressive revenue and profit growth, particularly over the past year, as evident by its 62.16% 12-month return. However, its small market capitalization and recent quarterly revenue decline raise some concerns. While the high profit margin of 78.01% is encouraging, a deeper dive into the company's fundamentals, industry trends, and competitive landscape is needed to determine if it's a good long-term buy.
To predict the Jenburkt Pharmaceuticals's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Jenburkt Pharmaceuticals Share Price Target For 2024
![Jenburkt Pharmaceuticals Targets For 2024 Chart](/wp-content/uploads/nip_uploads/charts/jenburph_thisyear_20240906.webp)
The line chart displays the monthly closing prices of Jenburkt Pharmaceuticals with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Jenburkt Pharmaceuticals shares in 2024, see the table below.
Advertisement
Jenburkt Pharmaceuticals Share Price Target Table For 2024
Jenburkt Pharmaceuticals's Levels | Value | Reason/Importance |
---|---|---|
2024 Target 3 | 1232.99 (+8.44%) | Price Action: Chart |
2024 Target 2 | 1210.00 (+6.42%) | Price Action: 05 Sep 2024 High |
2024 Target 1 | 1198.00 (+5.36%) | Price Action: 27 Aug 2024 High |
Current Price | 1137.00 | Jenburkt Pharmaceuticals's 1 share price as of Fri 06 Sep 2024 |
Stop Loss 1 | 1119.00 (-1.59%) | Price Action: 27 Aug 2024 Low |
Stop Loss 2 | 1105.00 (-2.82%) | Price Action: 26 Aug 2024 Low |
Stop Loss 3 | 1072.00 (-5.72%) | Price Action: 04 Sep 2024 Low |
Summary: Jenburkt Pharmaceuticals Share Price Prediction For 2024
In summary, Jenburkt Pharmaceuticals has surged by ₹456.85, achieving a notable +67.17% increase from 1st January 2024 to 06 Sep 2024. Our analysis of Jenburkt Pharmaceuticals for 2024 predicts an additional rise of 5.36% to 8.44% by the end of 2024 with three potential targets T1: 1198.00, T2: 1210.00, T3: 1232.99. Stop Loss at SL1: 1119.00, SL2: 1105.00, SL3: 1072.00.
Jenburkt Pharmaceuticals has a 52-week high of ₹1210.00, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹586.90, a critical support level - think of this as a safety net where the price might stop falling.
After looking at 2024's share price prediction, let's now check what 2025 might hold for Jenburkt Pharmaceuticals.
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Jenburkt Pharmaceuticals Share Price Target For 2025
![Jenburkt Pharmaceuticals Targets For 2025 Chart](/wp-content/uploads/nip_uploads/charts/jenburph_nextyear_20240906.webp)
The line chart displays the monthly closing prices of Jenburkt Pharmaceuticals with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Jenburkt Pharmaceuticals shares in 2025, see the table below.
Advertisement
Jenburkt Pharmaceuticals Share Price Target Table For 2025
Jenburkt Pharmaceuticals's Levels | Value | Reason/Importance |
---|---|---|
2025 Target 3 | 1563.40 (+37.5%) | Price Action: Chart |
2025 Target 2 | 1534.25 (+34.93%) | Custom Fibonacci Extension Lvl 64.9% |
2025 Target 1 | 1505.05 (+32.37%) | Fibonacci Extension Level 150% |
Current Price | 1137.00 | Jenburkt Pharmaceuticals's 1 share price as of Fri 06 Sep 2024 |
Stop Loss 1 | 980.00 (-13.81%) | Price Action: 19 Aug 2024 High |
Stop Loss 2 | 961.00 (-15.48%) | Price Action: 21 Aug 2024 Low |
Stop Loss 3 | 947.81 (-16.64%) | Technical Indicator: MA50 |
Summary: Jenburkt Pharmaceuticals Share Price Prediction For 2025
In summary, Jenburkt Pharmaceuticals has surged by ₹456.85, achieving a notable +67.17% increase from 1st January 2024 to 06 Sep 2024. Our analysis of Jenburkt Pharmaceuticals for 2025 predicts an additional rise of 32.37% to 37.5% by the end of 2025 with three potential targets T1: 1505.05, T2: 1534.25, T3: 1563.40. Stop Loss at SL1: 980.00, SL2: 961.00, SL3: 947.81.
Jenburkt Pharmaceuticals has a All-Time high of ₹1210.00, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹586.90, a critical support level - think of this as a safety net where the price might stop falling.
After looking at 2024's and 2025's share price prediction, you might wonder what are short term targets for Jenburkt Pharmaceuticals, we have created a specific page for that check here: Jenburkt Pharmaceuticals Share Price Target For Tomorrow & Next Week
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Jenburkt Pharmaceuticals Long Term Share Price Prediction Chart From 2024, 2025, 2026 to 2039
![Jenburkt Pharmaceuticals Targets Chart 2024, 2025, 2026 to 2039](/wp-content/uploads/nip_uploads/charts/jenburph_15years_20240906.webp)
This chart presents a detailed projection of Jenburkt Pharmaceuticals share price predictions from 2024, 2025, 2026 to 2039. This share price Prediction represents a CAGR of 14.27% over the next 15 years.
For complete year by year Jenburkt Pharmaceuticals long term share price target from 2024, 2025 to 2039 check the below table.
Jenburkt Pharmaceuticals Share Price Target Table From 2024, 2025, 2026 to 2039
Year | Jenburkt Pharmaceuticals Target | YoY Change % |
---|---|---|
2024 | ₹1,137 | [Current Price] |
2024 | ₹987.39 | -13.16% |
2025 | ₹1,456.24 | 47.48% |
2026 | ₹1,807.95 | 24.15% |
2027 | ₹1,995.96 | 10.39% |
2028 | ₹2,170.62 | 8.75% |
2029 | ₹2,602.16 | 19.88% |
2030 | ₹3,250.81 | 24.92% |
2031 | ₹3,595.39 | 10.59% |
2032 | ₹3,643.51 | 1.33% |
2033 | ₹3,708.46 | 1.78% |
2034 | ₹4,216.93 | 13.71% |
2035 | ₹5,045.37 | 19.64% |
2036 | ₹5,382.83 | 6.68% |
2037 | ₹5,291.05 | -1.71% |
2038 | ₹5,246.3 | -0.85% |
2039 | ₹6,391.29 | 21.82% |
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Jenburkt Pharmaceuticals Past Performance
![JENBURPH main](/wp-content/uploads/nip_uploads/charts/JENBURPH_main.webp)
- In 2000, Jenburkt Pharmaceuticals opening price was ₹8
- As of Fri 06 Sep 2024 the price stands at ₹1,137.
- This represents a Compound Annual Growth Rate (CAGR) of 21.93%.
- In 24 years, an investment of 10,000 would have become ₹14.21 Lakh.
As we wrap up, we hope you like our study on Jenburkt Pharmaceuticals share price predictions, please kindly note that these forecasts are based on technical analysis, past trends, and machine learning models. They are for educational purposes only, not investment advice.
Show Methodology We Use
Methodology Behind the Prediction
The share price predictions present on our site are derived from a robust model that incorporates multiple economic indicators, technical indicators, company performance metrics, and industry-specific factors.
We have historical share price data of all stocks for which we present targets, so we analyse historical trends from those past data and overlay them with projected market conditions to estimate future share prices of a stock.
- Jenburkt Pharmaceuticals Share Price History
- Jenburkt Pharmaceuticals Price Target Tomorrow
- Jenburkt Pharmaceuticals Dividend History
Disclaimer: Information is provided 'as is' and solely for informational and educational purposes, not for trading purposes or advice. We highly recommend to do your own research before making any investment.